311 related articles for article (PubMed ID: 36430263)
1. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
[TBL] [Abstract][Full Text] [Related]
2. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib as an emerging treatment for sarcoma.
Schöffski P; Blay JY; Ray-Coquard I
Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib for the Treatment of Sarcoma.
Blay JY; Duffaud F; George S; Maki RG; Penel N
Curr Treat Options Oncol; 2022 Nov; 23(11):1477-1502. PubMed ID: 36178573
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
[TBL] [Abstract][Full Text] [Related]
6. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
Tian Z; Niu X; Yao W
Front Oncol; 2020; 10():1642. PubMed ID: 32984034
[TBL] [Abstract][Full Text] [Related]
7. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Giordano G; Merlini A; Ferrero G; Mesiano G; Fiorino E; Brusco S; Centomo ML; Leuci V; D'Ambrosio L; Aglietta M; Sangiolo D; Grignani G; Pignochino Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831119
[TBL] [Abstract][Full Text] [Related]
8. Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma.
Fleuren EDG; Vlenterie M; van der Graaf WTA
Front Oncol; 2023; 13():1013359. PubMed ID: 36994209
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
[TBL] [Abstract][Full Text] [Related]
10. Real-world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study.
Peretz Soroka H; Vora T; Noujaim J; Marcoux N; Cohen-Gogo S; Alcindor T; Holloway C; Rodrigues C; Karachiwala H; Alvi S; Lee U; Cheng S; Banerji S; Oberoi S; Feng X; Smrke A; Simmons C; Razak AA; Gupta AA
Cancer Med; 2023 Sep; 12(18):18872-18881. PubMed ID: 37724607
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma.
Just MA; Van Mater D; Wagner LM
Pediatr Blood Cancer; 2021 Aug; 68(8):e29084. PubMed ID: 33894051
[TBL] [Abstract][Full Text] [Related]
12. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma).
Anderson P; Kopp L; Anderson N; Cornelius K; Herzog C; Hughes D; Huh W
Expert Opin Investig Drugs; 2008 Nov; 17(11):1703-15. PubMed ID: 18922107
[TBL] [Abstract][Full Text] [Related]
13. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.
Fleuren ED; Versleijen-Jonkers YM; Boerman OC; van der Graaf WT
Biochim Biophys Acta; 2014 Apr; 1845(2):266-76. PubMed ID: 24582852
[TBL] [Abstract][Full Text] [Related]
14. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions.
Geryk-Hall M; Hughes DP
Curr Oncol Rep; 2009 Nov; 11(6):446-53. PubMed ID: 19840522
[TBL] [Abstract][Full Text] [Related]
15. Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes.
Bajpai J; Khanna N; Vora T; Gulia A; Laskar S; Puri A; Sanduptla B; Chinnaswamy G; Nayak P; Juvekar SL; Janu A; Desai S; Ghosh J; Purandare N; Ramadwar M; Rangarajan V; Rekhi B
Indian J Cancer; 2018; 55(1):37-44. PubMed ID: 30147091
[TBL] [Abstract][Full Text] [Related]
16. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
[TBL] [Abstract][Full Text] [Related]
17. The 'other' bone sarcomas in Japan: a retrospective study of primary bone sarcomas other than osteosarcoma, Ewing sarcoma and chondrosarcoma, using data from the Bone Tumuor Registry in Japan.
Nagano A; Tsugita M; Nishimoto Y; Akiyama H; Kawai A
Jpn J Clin Oncol; 2021 Aug; 51(9):1430-1436. PubMed ID: 34105731
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
19. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]